121 related articles for article (PubMed ID: 23496868)
41. HIV treatment outcomes following antiretroviral therapy initiation and monitoring: A workplace program in Papua, Indonesia.
Limmade Y; Fransisca L; Rodriguez-Fernandez R; Bangs MJ; Rothe C
PLoS One; 2019; 14(2):e0212432. PubMed ID: 30802257
[TBL] [Abstract][Full Text] [Related]
42. Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.
Brooks K; Diero L; DeLong A; Balamane M; Reitsma M; Kemboi E; Orido M; Emonyi W; Coetzer M; Hogan J; Kantor R
J Int AIDS Soc; 2016; 19(1):20798. PubMed ID: 27231099
[TBL] [Abstract][Full Text] [Related]
43. [Study on the relationship between HIV drug resistance and CD4(+)T cell counts among antiretroviral therapy patients with low viral load].
Liu PT; Xing H; Liao LJ; Leng XB; Wang J; Kan W; Yan J; Zuo ZB; Ruan YH; Shao YM
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Mar; 52(3):277-281. PubMed ID: 29973007
[No Abstract] [Full Text] [Related]
44. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
45. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.
Mussini C; Lorenzini P; Cozzi-Lepri A; Lapadula G; Marchetti G; Nicastri E; Cingolani A; Lichtner M; Antinori A; Gori A; d'Arminio Monforte A;
Lancet HIV; 2015 Mar; 2(3):e98-106. PubMed ID: 26424550
[TBL] [Abstract][Full Text] [Related]
46. Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS.
Marconi VC; Grandits G; Okulicz JF; Wortmann G; Ganesan A; Crum-Cianflone N; Polis M; Landrum M; Dolan MJ; Ahuja SK; Agan B; Kulkarni H;
PLoS One; 2011; 6(5):e17956. PubMed ID: 21625477
[TBL] [Abstract][Full Text] [Related]
47. Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda.
Rusine J; Asiimwe-Kateera B; van de Wijgert J; Boer KR; Mukantwali E; Karita E; Gasengayire A; Jurriaans S; de Jong M; Ondoa P
PLoS One; 2013; 8(8):e64345. PubMed ID: 23950859
[TBL] [Abstract][Full Text] [Related]
48. Validation of CD4
Cassenote AJF; Grangeiro A; Escuder MM; Abe JM; Segurado AAC
BMC Infect Dis; 2018 Dec; 18(1):617. PubMed ID: 30514215
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections.
Church D; Gregson D; Lloyd T; Klein M; Beckthold B; Laupland K; Gill MJ
J Clin Microbiol; 2011 Jan; 49(1):118-24. PubMed ID: 21084515
[TBL] [Abstract][Full Text] [Related]
50. Mobile Text Messaging to Improve Medication Adherence and Viral Load in a Vulnerable Canadian Population Living With Human Immunodeficiency Virus: A Repeated Measures Study.
King E; Kinvig K; Steif J; Qiu AQ; Maan EJ; Albert AY; Pick N; Alimenti A; Kestler MH; Money DM; Lester RT; Murray MCM
J Med Internet Res; 2017 Jun; 19(6):e190. PubMed ID: 28572079
[TBL] [Abstract][Full Text] [Related]
51. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
[TBL] [Abstract][Full Text] [Related]
52. Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort.
Jarzebowski W; Caumes E; Dupin N; Farhi D; Lascaux AS; Piketty C; de Truchis P; Bouldouyre MA; Derradji O; Pacanowski J; Costagliola D; Grabar S;
Arch Intern Med; 2012 Sep; 172(16):1237-43. PubMed ID: 22826097
[TBL] [Abstract][Full Text] [Related]
53. "Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.
Wood E; Hogg RS; Yip B; Tyndall MW; Sherlock CH; Harrigan RP; O'Shaughnessy MV; Montaner JS
J Acquir Immune Defic Syndr; 2002 Jun; 30(2):159-66. PubMed ID: 12045678
[TBL] [Abstract][Full Text] [Related]
54. A pseudo-random patient sampling method evaluated.
De La Mata NL; Ahn MY; Kumarasamy N; Ly PS; Ng OT; Nguyen KV; Merati TP; Pham TT; Lee MP; Durier N; Law MG
J Clin Epidemiol; 2017 Jan; 81():129-139. PubMed ID: 27771357
[TBL] [Abstract][Full Text] [Related]
55. Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients.
Otegbayo JA; Taiwo BO; Akingbola TS; Odaibo GN; Adedapo KS; Penugonda S; Adewole IF; Olaleye DO; Murphy R; Kanki P
Ann Hepatol; 2008; 7(2):152-6. PubMed ID: 18626434
[TBL] [Abstract][Full Text] [Related]
56. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
Gianotti N; Lorenzini P; Cozzi-Lepri A; De Luca A; Madeddu G; Sighinolfi L; Pinnetti C; Santoro C; Meraviglia P; Mussini C; Antinori A; d'Arminio Monforte A;
J Antimicrob Chemother; 2019 Sep; 74(9):2732-2741. PubMed ID: 31173639
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arastéh K; Schürmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fätkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sørensen B
Lancet Infect Dis; 2014 Apr; 14(4):291-300. PubMed ID: 24525316
[TBL] [Abstract][Full Text] [Related]
58. Participation in clinical trials among women living with HIV in Canada. Canadian Women's HIV Study Group.
Hankins C; Lapointe N; Walmsley S
CMAJ; 1998 Dec; 159(11):1359-65. PubMed ID: 9861204
[TBL] [Abstract][Full Text] [Related]
59. Association Between CD4
Islam M; Ramesh N; Kolman S; Koshy S; Frank M; Salomon N; Miller A; Harris M
Lung; 2017 Oct; 195(5):635-642. PubMed ID: 28647827
[TBL] [Abstract][Full Text] [Related]
60. Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm3: CPCRA 059.
Abrams DI; Bebchuk JD; Denning ET; Davey RT; Fox L; Lane HC; Sampson J; Verheggen R; Zeh D; Markowitz NP;
J Acquir Immune Defic Syndr; 2002 Mar; 29(3):221-31. PubMed ID: 11873071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
